Country for PR: United States
Contributor: PR Newswire New York
Wednesday, May 15 2019 - 10:16
Pneuma Respiratory and Leads Biolabs, Inc. Announce Partnership
BOONE, North Carolina, May 15, 2019 /PRNewswire-AsiaNet/ --

Pneuma Respiratory, Inc., developer of a proprietary breath-activated digital 
inhaler (BDI), and Leads Biolabs Inc. announce an agreement granting Pneuma an 
exclusive license to develop Leads Biolabs' panel of immuno-oncology monoclonal 
antibodies and fusion protein molecules for the pulmonary delivery of Leads' 
antibodies and molecules.  Using Pneuma's digital inhaler platform, the 
agreement provides access to the untapped potential of pulmonary delivery of 
Leads' immuno-oncology therapies in the treatment of oncologic or 
immune-mediated lung diseases.  

Logo - 

In a recent publication, Pneuma announced the completion of a study 
demonstrating the feasibility of antibody delivery to the lungs via its digital 
inhaler platform.  This study, conducted in an animal model, indicates that the 
Pneuma digital inhaler platform may provide a method for the pulmonary delivery 
of monoclonal antibody therapies, enabling the targeted treatment of oncologic 
or immune-mediated lung diseases. 

"This collaboration is an exciting development for the field of 
immuno-oncology," said Ronald Bukowski, MD, physician emeritus, Cleveland 
Clinic Foundation.  "Approaches utilizing the regional administration of novel 
checkpoint inhibitors may provide new treatment opportunities for patients with 
a variety of malignancies."

"We are pleased to enter into a license agreement for Leads Biolabs monoclonal 
antibody portfolio," said Pneuma Chief Executive Officer and co-founder Eric 
Hunter. "We look forward to working with their team to conduct studies that may 
lead to positive change in the future treatment of non-small cell lung cancer."

Dr. Xiaoqiang Kang, Chairman and CEO of Leads Biolabs, said: "We are very 
excited to have this license agreement with Pneuma Respiratory. The commitment 
by a leader in digital pulmonary delivery of drugs is an endorsement of the 
value of our portfolio. We believe that Pneuma's digital inhaler technology 
combined with our antibody drugs will create very exciting new opportunities 
for both companies. We look forward to working with Pneuma to move our 
candidates into the clinic as quickly as possible."

About Pneuma Respiratory: 
Launched in 2015, Pneuma Respiratory is a pharmaceutical company based in 
Boone, North Carolina. With a global team of researchers, physicians, designers 
and engineers, Pneuma has created the first fully integrated digital 
breath-activated inhaler. This inhaled delivery system includes digital 
micro-fluidics integrated with Bluetooth technology capable of providing 
feedback on drug delivery to patients, family members, and health care 
providers. Using Pneuma's digital droplet ejector technology, Pneuma's device 
has the potential to ultimately deliver a spectrum of novel therapies, 
including biologics, to the lungs. The first breath-activated digital inhaler 
(BDI) is currently in use for investigational purposes only and is not yet 
commercially available. For more information, please visit

About Leads Biolabs, Inc.:
Leads Biolabs, Inc., a Maryland Corporation, is the fully-owned subsidiary of a 
US-Sino joint venture company, Nanjing Leads Biolabs Co., Ltd. based in 
Nanjing, China. Leads Biolabs is an innovation-driven biopharmaceutical company 
with a rich portfolio of more than 10 novel mono-targeted or bispecific 
antibody drug projects for cancer immunotherapy and other major diseases to 
fulfill unmet medical needs. For more information, please visit

Christy Anglin

SOURCE: Pneuma Respiratory